AbbVie forecast 2025 profit above estimates on Friday, as strong sales of its newer immunology drugs Skyrizi and Rinvoq make up for a steep decline in those of Humira, its flagship rheumatoid ...

Jan 10 (Reuters) - Abbvie (ABBV.N), opens new tab said on Friday it would record a charge of about $3.5 billion related to its experimental schizophrenia drug, emraclidine, which recently failed ...

AbbVie holds a strong portfolio of marketed and pipeline drugs. While the increasing competition to the company's key drug Humira should slow the growth for the company in the near term, we ...

The failure of Cerevel's emraclidine in schizophrenia will cost AbbVie an impairment charge of about $3.5 billion, the pharma said in a Jan. 10 filing with the Securities and Exchange Commission.